BR112017016465A2 - composto heterocíclico e composição farmacêutica que o compreende - Google Patents
composto heterocíclico e composição farmacêutica que o compreendeInfo
- Publication number
- BR112017016465A2 BR112017016465A2 BR112017016465-5A BR112017016465A BR112017016465A2 BR 112017016465 A2 BR112017016465 A2 BR 112017016465A2 BR 112017016465 A BR112017016465 A BR 112017016465A BR 112017016465 A2 BR112017016465 A2 BR 112017016465A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- heterocyclic compound
- heterocyclic
- compound
- pharmaceutical
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2015-0017339 | 2015-02-04 | ||
| KR20150017339 | 2015-02-04 | ||
| PCT/KR2016/001133 WO2016126085A2 (ko) | 2015-02-04 | 2016-02-02 | 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017016465A2 true BR112017016465A2 (pt) | 2018-06-19 |
| BR112017016465B1 BR112017016465B1 (pt) | 2023-11-14 |
Family
ID=56564854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017016465-5A BR112017016465B1 (pt) | 2015-02-04 | 2016-02-02 | Composto heterocíclico e composição farmacêutica que o compreende |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10227328B2 (pt) |
| EP (1) | EP3255042B1 (pt) |
| JP (1) | JP6615899B2 (pt) |
| KR (1) | KR101783642B1 (pt) |
| CN (1) | CN107250130B (pt) |
| AU (1) | AU2016216253B2 (pt) |
| BR (1) | BR112017016465B1 (pt) |
| CA (1) | CA2974788C (pt) |
| DK (1) | DK3255042T3 (pt) |
| ES (1) | ES2854707T3 (pt) |
| IL (1) | IL253538B (pt) |
| RU (1) | RU2710743C2 (pt) |
| SG (1) | SG11201705952SA (pt) |
| WO (1) | WO2016126085A2 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110038A1 (es) | 2016-05-26 | 2019-02-20 | Kalyra Pharmaceuticals Inc | Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos |
| US20210198238A1 (en) * | 2018-08-30 | 2021-07-01 | The Regents Of The University Of California | Ire1 kinase inhibitors and uses thereof |
| EA202191938A1 (ru) * | 2019-01-29 | 2021-10-13 | Бета Фарма, Инк. | Производные 2h-индазола в качестве терапевтических средств при видах рака головного мозга и метастазах в головной мозг |
| WO2021045586A1 (ko) * | 2019-09-06 | 2021-03-11 | 비욘드바이오주식회사 | 2'-아미노-6-(2-아미노-6-(1-이소프로필피페리딘-4-일)-5-메틸피리미딘-4-일)-3'-플루오로-[2,4'-바이피리딘]-5-올 3염산염 및 이를 포함하는 약제학적 조성물 |
| KR20210029694A (ko) | 2019-09-06 | 2021-03-16 | 비욘드바이오주식회사 | 2'-아미노-6-(2-아미노-6-메틸피리미딘-4-일)-3'-플루오로-[2,4'-바이피리딘]-5-올 2염산염 및 이를 포함하는 약제학적 조성물 |
| KR20210029693A (ko) | 2019-09-06 | 2021-03-16 | 비욘드바이오주식회사 | 2,6-비스-(2-아미노피리미딘-4-일)피리딘-3-올 2염산염 및 이를 포함하는 약제학적 조성물 |
| KR102443873B1 (ko) | 2019-09-06 | 2022-09-19 | 비욘드바이오주식회사 | 피리미딘일 바이피리딘 화합물의 제조방법 및 그를 위한 중간체 |
| WO2021100677A1 (ja) * | 2019-11-18 | 2021-05-27 | 中外製薬株式会社 | 併用医薬 |
| CN111558044B (zh) * | 2020-06-01 | 2022-02-11 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种包含舒尼替尼的药物组合物及其制剂和应用 |
| CN116082310B (zh) * | 2023-02-17 | 2024-08-20 | 厦门大学 | 联吡啶酰胺类衍生物及其制备和应用 |
| CN116751195A (zh) * | 2023-06-21 | 2023-09-15 | 杭州科兴生物化工有限公司 | 联吡啶类化合物、其可药用的盐以及制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| GB0013655D0 (en) * | 2000-06-05 | 2000-07-26 | Prolifix Ltd | Therapeutic compounds |
| KR100850728B1 (ko) * | 2000-06-12 | 2008-08-06 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 1,2-디하이드로피리딘 화합물, 그의 제조 방법 및 그의 용도 |
| AU2002310187A1 (en) * | 2001-05-30 | 2002-12-09 | Lg Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
| GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| NZ538715A (en) * | 2002-08-14 | 2007-07-27 | Vertex Pharma | Protein kinase inhibitors and uses thereof |
| CN1742723A (zh) | 2004-09-02 | 2006-03-08 | 天津倍方科技发展有限公司 | 含有替莫唑胺－8－羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途 |
| WO2008106202A1 (en) * | 2007-02-27 | 2008-09-04 | Housey Gerard M | Theramutein modulators |
| WO2010018458A2 (en) * | 2008-08-12 | 2010-02-18 | Crystalgenomics, Inc. | Phenol derivatives and methods of use thereof |
-
2016
- 2016-02-02 JP JP2017541860A patent/JP6615899B2/ja active Active
- 2016-02-02 WO PCT/KR2016/001133 patent/WO2016126085A2/ko active Application Filing
- 2016-02-02 ES ES16746826T patent/ES2854707T3/es active Active
- 2016-02-02 KR KR1020160013029A patent/KR101783642B1/ko active IP Right Grant
- 2016-02-02 CN CN201680008749.8A patent/CN107250130B/zh active Active
- 2016-02-02 CA CA2974788A patent/CA2974788C/en active Active
- 2016-02-02 DK DK16746826.3T patent/DK3255042T3/da active
- 2016-02-02 US US15/546,714 patent/US10227328B2/en active Active
- 2016-02-02 SG SG11201705952SA patent/SG11201705952SA/en unknown
- 2016-02-02 BR BR112017016465-5A patent/BR112017016465B1/pt active IP Right Grant
- 2016-02-02 AU AU2016216253A patent/AU2016216253B2/en active Active
- 2016-02-02 EP EP16746826.3A patent/EP3255042B1/en active Active
- 2016-02-02 RU RU2017130825A patent/RU2710743C2/ru active
-
2017
- 2017-07-18 IL IL253538A patent/IL253538B/en active IP Right Grant
-
2019
- 2019-01-07 US US16/241,177 patent/US10611754B2/en active Active
-
2020
- 2020-02-21 US US16/798,134 patent/US20200190062A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160096033A (ko) | 2016-08-12 |
| JP6615899B2 (ja) | 2019-12-04 |
| BR112017016465B1 (pt) | 2023-11-14 |
| RU2710743C2 (ru) | 2020-01-10 |
| CA2974788A1 (en) | 2016-08-11 |
| CA2974788C (en) | 2023-04-11 |
| CN107250130B (zh) | 2019-11-08 |
| IL253538A0 (en) | 2017-09-28 |
| WO2016126085A2 (ko) | 2016-08-11 |
| AU2016216253A1 (en) | 2017-08-17 |
| SG11201705952SA (en) | 2017-09-28 |
| US20180273510A1 (en) | 2018-09-27 |
| WO2016126085A3 (ko) | 2016-11-03 |
| EP3255042A4 (en) | 2018-08-01 |
| EP3255042A2 (en) | 2017-12-13 |
| JP2018504449A (ja) | 2018-02-15 |
| RU2017130825A (ru) | 2019-03-04 |
| NZ734084A (en) | 2023-09-29 |
| US10611754B2 (en) | 2020-04-07 |
| KR101783642B1 (ko) | 2017-10-10 |
| CN107250130A (zh) | 2017-10-13 |
| US20200190062A1 (en) | 2020-06-18 |
| DK3255042T3 (da) | 2021-02-08 |
| AU2016216253B2 (en) | 2019-11-21 |
| ES2854707T3 (es) | 2021-09-22 |
| RU2017130825A3 (pt) | 2019-08-12 |
| EP3255042B1 (en) | 2020-12-30 |
| IL253538B (en) | 2020-09-30 |
| US20190135786A1 (en) | 2019-05-09 |
| US10227328B2 (en) | 2019-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3529248T3 (da) | Farmaceutiske sammensætninger | |
| DK3495023T3 (da) | Semifluorerede forbindelser og sammensætninger deraf | |
| BR112017016465A2 (pt) | composto heterocíclico e composição farmacêutica que o compreende | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| BR112016015706A2 (pt) | composto, uso do mesmo e composição farmacêutica | |
| DK3416996T3 (da) | Hærdelig sammensætning | |
| DK3102200T3 (da) | Terapeutisk forbindelse og sammensætning | |
| DK3529240T3 (da) | Farmaceutiske forbindelser | |
| DK3532029T3 (da) | Flydende farmaceutisk sammensætning | |
| DK3554534T3 (da) | Farmaceutisk sammensætning omfattende insulin | |
| DK3528902T3 (da) | Ringegelsammensætning | |
| DK3275452T3 (da) | Farmaceutisk sammensætning med silibinin | |
| DK3583943T3 (da) | Farmaceutisk sammensætning | |
| DK3256479T3 (da) | 4-substituerede benzoxaborolforbindelser og anvendelser deraf | |
| DK3672948T3 (da) | Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser | |
| PT3202759T (pt) | Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo | |
| DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf | |
| DK3328368T3 (da) | Forbindelser og farmaceutisk sammensætning associeret med ubiquitinering-proteasomsystem | |
| DK3393254T3 (da) | Sammensætning | |
| DK3302483T3 (da) | Farmaceutiske sammensætninger og anvendelse deraf | |
| DK3416502T3 (da) | Glykæmisk-reducerende sammensætning | |
| DK3288933T3 (da) | Oxindolforbindelser og farmaceutiske sammensætninger deraf | |
| DK3357520T3 (da) | Viskoelastisk sammensætning | |
| DK3256138T3 (da) | Farmaceutiske sammensætninger omfattende meloxicam | |
| DK3322295T3 (da) | Sammensætning |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/02/2016, OBSERVADAS AS CONDICOES LEGAIS |